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While targeting VEGF has shown success against a number of human cancers, drug resistance has resulted
in compromised clinical benefits. In this issue of Cancer Cell, Crawford et al. (2009) report that tumors
resistant to anti-VEGF therapy stimulate tumor-associated fibroblasts to express proangiogenic PDGF-C,
implicating it as a potential therapeutic target.One of the early hopes for the use of anti-
angiogenic drugs for cancer treatment
was that they would be much less likely
to lose their therapeutic activity as a result
of tumor-acquired resistance over time
(Kerbel, 1991). The theory posited that
a drug targeting genetically stable
(normal) host cells—namely, vascular
endothelial cells, rather than highly
mutable, genetically unstable tumor cells
(a major driving force responsible for
acquired resistance to other anticancer
drugs)—would be less likely to elicit resis-
tance or tolerance. Aside from the fact
that the assumption of genetic stability
for endothelial cells in tumor blood
vessels may not always be correct (Hida
and Klagsbrun, 2005), clinical experience
has unequivocally shown that acquired
resistance to antiangiogenic drugs is inev-
itable (Bergers and Hanahan, 2008; Ker-
bel, 2008). Virtually all patients whose
tumors initially respond to drugs such as
bevacizumab (monoclonal antibody to
VEGF), sorafenib, or sunitinib (small-
molecule receptor tyrosine kinase inhibi-
tors targeting VEGF receptors and PDGF
receptors, among others) eventually
become nonresponsive, often within
months of therapy initiation (Kerbel,
2008). In addition, there are significant
proportions of patients whose tumors
are intrinsically resistant to such drugs,
even when the intended drug targets,
i.e., VEGF and VEGF receptors (especially
VEGFR-2), are present in abundance. As
a result, a rapidly growing area in tumor
angiogenesis research is the elucidationof the mechanisms responsible for both
intrinsic and acquired resistance to anti-
angiogenic agents (Bergers and Hana-
han, 2008).
Although the current literature is limited,
the number and diversity of mechanisms
that have already been implicated is
both biologically fascinating and thera-
peutically discouraging. With respect
to acquired resistance, upregulation of
compensatory proangiogenic pathways
is one well-known proposed mechanism.
Thus, targeting the VEGF pathway may
lead to the emergence and overgrowth of
tumor cell subpopulations, driven in part
by drug-induced elevated levels of tumor
hypoxia, which can induce neovasculari-
zation simply by producing a different
proangiogenic mediator such as basic
fibroblast growth factor (bFGF) (Casa-
novas et al., 2005). Additional mecha-
nisms include selection of mutant tumor
cells that have an enhanced ability to
survive and grow under elevated hypoxia
conditions, rapid remodeling/matura-
tion of the tumor vasculature during
treatment, and even co-option of normal
vasculature incertain vascular-richorgans
(see Bergers and Hanahan, 2008 for
review). With respect to intrinsic resis-
tance, aside from the absence of the drug
target, alternative cellular mediators of
angiogenesis—e.g., the recruitment and
infiltration of tumors by proangiogenic but
VEGF-independent circulating myeloid
Gr1+CD11b+ cells (Shojaei et al., 2007)—
were reported to be another possible
mechanism.Cancer CeIn this issue of Cancer Cell, Crawford
et al. (2009) report a new mechanism
for intrinsic resistance to anti-VEGF
antibodies, namely, that tumor cells
refractory to anti-VEGF therapy in some
manner stimulate adjacent tumor-associ-
ated fibroblasts (TAFs) to secrete platelet-
derived growth factor C (PDGF-C), which
in turn stimulates tumor angiogenesis.
The authors studied two transplantable
mouse lymphomas, one responsive (TIB6)
and one intrinsically refractory (EL4) to
anti-VEGF antibody therapy. Usingmicro-
array analysis, the authors found that
TAFs isolated from refractory EL4 tumors
upregulated PDGF-C mRNA. Using a
neutralizing antibody, the authors impli-
cated PDGF-C in promoting both angio-
genesis and thegrowth of EL4 tumors pro-
gressing under anti-VEGF therapy. Thus,
these results show that targeting VEGF
can produce yet another compensatory
proangiogenic mediator, but surprisingly,
in this case, the source of the redundancy
was not the tumor cell population per
se, but rather one of its stromal cell
components.
The results of Crawford et al. add a new
twist by which TAFs can influence tumor
angiogenesis. For example, previous
studies have implicated such cells as
a possible major source of endogenous
VEGF driving tumor angiogenesis (Fuku-
mura et al., 1998). With respect to drug-
induced changes in TAFs, trastuzumab
treatment was shown to upregulate the
endogenous angiogenesis inhibitor throm-
bospondin 1 (TSP1) in TAFs, which mayll 15, January 6, 2009 ª2009 Elsevier Inc. 3
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‘‘side’’ effects of this drug (Izumi et al.,
2002). Similarly, the antiangiogenic effects
of low-dose metronomic chemotherapy
may be caused by upregulation of TSP1
(Bocci et al., 2003), occurring in part within
the TAF population (Hamano et al., 2004).
However, in contrast to the results of
Crawford et al., such changes do not facil-
itate resistance to such drugs, but rather
the contrary.
The secretion of PDGF-C by TAFs once
again highlights the importance of the
tumormicroenvironment in tumor biology.
It also provides further evidence that
nonmalignant stromal cells are not neces-
sarily innocent bystanders in the tumor
milieu. Rather, they can be active consig-
lieri, conspiring to stimulate tumor growth,
metastasis, and perhaps even response
to antiangiogenic therapy (see Figure 1).
Like any new and provocative finding,
the Crawford et al. study raises many
questions. The authors used two trans-
plantable lymphomas for their studies in
part because fibroblasts can be isolated
relatively easily from such tumors. Will
the results apply to carcinomas and
sarcomas? The studies undertaken
involved mainly intrinsic resistance and
as such lead one to ask whether acquired
resistance to VEGF pathway-targeting
drugs might also be mediated by upregu-
lation of PDGF-C in TAFs. What might the
implications of the findings be for small-
molecule drugs such as sunitinib or sora-
fenib that target not only VEGF receptors
but also PDGF receptors, which can bind
PDGF-C? Could this be a factor in their
robust single-agent activity in renal cell
or hepatocellular carcinoma patients, in
contrast to bevacizumab, which is
currently approved for use only in combi-
nation with chemotherapy? Also with
respect to the issue of clinical relevance,
could the results of Crawford et al. help
explain the phase III clinical trial failure of
bevacizumab treatment (when combined
with weekly gemcitabine) for pancreatic
cancer? As noted by the authors, pancre-
atic cancers are often heavily infiltrated
by fibroblasts. Conversely, in situations
where bevacizumab does provide
a benefit when combined with chemo-
therapy—something not modeled in the
Crawford et al. studies—would PDGF-C
upregulation provide escape from such
combination treatment regimens, or solely
from anti-VEGF monotherapy? And what
about mechanisms of acquired resistance
to drugs such as sunitinib or sorafenib?
Such resistance infers additional path-
ways of resistance. Indeed, the VEGF-
refractory EL4 tumor model was previ-
ously reported to recruit and subsequently
‘‘prime’’ bone marrow-derived circulating
Gr1+CD11b+ myeloid cells to stimulate
tumor angiogenesis, even in the presence
of VEGF-neutralizing antibodies.
The approval of the first antiangiogenic
agents for cancer therapy set off a wave of
excitement. Now, the dawning realization
is that tumors possess an embarrassment
of riches when it comes to intrinsic, induc-
ible, and/or acquired mechanisms to
evade antiangiogenic therapies. Uncover-
ing such mechanisms, of which PDGF-C
upregulation is the latest addition, should
hopefully lead to strategies that cause
growth delays in tumors that evade and
then relapse to first-line antiangiogenic
therapies (Figure 1). In this scenario, the
ultimate target will not likely be a single
molecule, but rather the gradual yet signif-
icant extension of survival brought about
by additional lines of therapy aimed at
multiple different targets.
ACKNOWLEDGMENTS
R.S.K. is a consultant to GlaxoSmithKline and
Taiho Pharmaceutical Co. and a member of the
scientific advisory board of MolMed S.p.A. and
Oxigene, Inc.; has served as a consultant to
ImClone Systems; is a recipient of honoraria from
Pfizer andGenentech/Roche; and has a sponsored
research agreement with GlaxoSmithKline.
REFERENCES
Bergers, G., and Hanahan, D. (2008). Nat. Rev.
Cancer 8, 592–603.
Bocci, G., Francia, G., Man, S., Lawler, J., and
Kerbel, R.S. (2003). Proc. Natl. Acad. Sci. USA
100, 12917–12922.
Casanovas, O., Hicklin, D., Bergers, G., and Hana-
han, D. (2005). Cancer Cell 8, 299–309.
Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X.,
Modrusan, Z., Kaminker, J., and Ferrara, N. (2009).
Cancer Cell 15, this issue, 21–34.
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y.,
Park, E.C., Lu, N., Selig, M., Nielsen, G., Taksir,
Figure 1. Model of Resistance to Anti-VEGF Therapy Mediated by Tumor-Associated
Fibroblasts
Schematic graph shows relative tumor growth over time of a tumor responsive to administration of anti-
VEGF therapy (A), leading to initial regression (B). Crawford et al. (2009) report that tumors refractory to
anti-VEGF therapy stimulate tumor-associated fibroblasts (TAFs) to secrete the proangiogenic factor
PDGF-C, which compensates for the neutralization of VEGF and promotes tumor angiogenesis (C).
Although their results were obtained with tumors intrinsically resistant to anti-VEGF therapy (as in C), their
results imply that the same mechanismmay arise in tumors that develop acquired resistance and suggest
that PDGF-C targeting may be an effective second-line therapy.
4 Cancer Cell 15, January 6, 2009 ª2009 Elsevier Inc.
Cancer Cell
PreviewsT., Jain, R.K., and Seed, B. (1998). Cell 94, 715–
725.
Hamano, Y., Sugimoto, H., Soubasakos, M.A.,
Kieran, M., Olsen, B.R., Lawler, J., Sudhakar, A.,
and Kalluri, R. (2004). Cancer Res. 64, 1570–
1574.Unholy Matrimony
as Malignant Partn
John M. Maris1,2,*
1Division of Oncology and Center for Childhoo
2Department of Pediatrics and Abramson Fam
Philadelphia, PA 19104, USA
*Correspondence: maris@chop.edu
DOI 10.1016/j.ccr.2008.12.008
Aurora A is amitotic kinase that is es
Otto et al. report that Aurora A int
sequesters it from proteolytic degra
a therapeutic target.
The Aurora kinases have attracted intense
scrutiny in recent years due to accumu-
lating evidence that they often act as
oncogenic drivers inmany humancancers
(Gautschi et al., 2008). The Aurora family
consists of three known gene paralogs
(AURKA, AURKB, and AURKC) that are
key regulators of mitosis. The genes
each encode serine/threonine kinases
with a significant degree of homology in
the C-terminal catalytic domain, suggest-
ing that the divergent N-terminal domains
distinguish their diverse effects on the cell
cycle and mitosis. While little is known
about Aurora C, and Aurora B appears to
play a regulatory role throughout mitosis,
recent evidence strongly suggests that
Aurora A has a more restricted role in the
cell cycle and is absolutely required for
the G2/M transition via phosphorylation
of polo-like kinase 1 in concert with the
cofactor Bora (Macurek et al., 2008; Sasai
et al., 2008). In addition, Aurora A is critical
for mitotic spindle assembly and stability,
as well as regulation of centrosomal and
kinetochore formation (Marumoto et al.,
2005). It is therefore not surprising that
Aurora A expression is tightly regulated
throughout normal development and the
cell cycle and that engineered AurkaHida, K., and Klagsbrun, M. (2005). Cancer Res.
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and there has been interest in leveraging
this fact therapeutically (Gautschi et al.,
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Likewise, theMyc family of transcription
factors is commonly deregulated in
cancer, via chromosomal translocation
events, gene amplification, and interfer-
ence with normal protein degradative
pathways. In the childhood cancer neuro-
blastoma, MYCN is highly amplified in
about 20% of cases, and these are
uniformly very aggressive neoplasms
with patients showing a poor survival
probability. Importantly, there are another
20%–30% of cases that behave in an
equally aggressive fashion but in which
the tumors do not harbor amplification of
theMYCN locus or other mechanisms for
MYCN overexpression. Strikingly, these
tumors typically overexpress MYC via
mechanisms yet to be determined (Liu
et al., 2008). While both the Aurora and
Myc gene families seem to be obvious
candidates for anticancer drug develop-
ment, the Auroras theoretically provide
a much more tractable therapeutic target
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miscuous and weak transcription factors
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In this issue of Cancer Cell, Otto et al.
(2009) identify Aurora A and N-Myc as
oncogenic partners in neuroblastoma,with
Aurora A functioning to sequester N-Myc
away from ubiquitin-mediated proteolytic
degradation. Using a synthetic-lethal
screening strategy in neuroblastoma cell
line models, the investigators knocked
down 194 separate genes selected to be
candidates for allowing neural progenitor
cells to survive deregulatedMYCN (forced
overexpression ofMYCN in neural progen-
itor cell models or MYCN-nonamplified
neuroblastomas results in immediate
induction of programmed cell death).
These were genes overexpressed in
MYCN-amplified tumors and/or genes
with direct evidence for being aMyc target.
AURKA was one of 17 genes that showed
selective antiproliferative effects in the
MYCN-amplified cells when the protein
was knocked down. In a series of elegant
and well-controlled experiments, Otto and
colleagues demonstrated that Aurora A
stabilizes the N-Myc protein through
a direct physical interaction and interferes
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